Clinical Research of CBD

//Clinical Research of CBD

Clinical Research of CBD

Cannabidiol (CBD) is a cannabinoid that is getting much attention from the scientific and medical communities. It is found in industrial hemp, which contains only trace amounts of tetrahydrocannabinol (THC), the psychoactive component in marijuana. Smaller amounts of CBD occur in marijuana than in hemp, varying with the strain. Clinical research of CBD is being conducted in numerous countries to evaluate its efficacy and potential therapeutic applications.

In the United States, producers and sellers of industrial hemp and its products, including those containing CBD, are cautioned by the US Food and Drug Administration (FDA) about making claims regarding health or medical benefits that have not been verified by the FDA. However, the FDA supports clinical research approved through an application process involving several federal agencies. Following are some of the health and medical conditions for which studies are and/or have been conducted, including some documented in the National Institutes of Health’s US Library of Medicine:

  • Acne
  • Alcoholism
  • Anxiety
  • Bone fracture healing
  • Cancer – specific studies show suppression of colon tumors and breast cancer cells
  • Cancer pain
  • Cardiovascular disease
  • Chronic pain
  • Cigarette addiction
  • Diabetes
  • Epilepsy
  • Fibromyalgia
  • Migraines and other headaches
  • Multiple Sclerosis
  • Neurodegenerative disorders including Huntington’s disease
  • Neuro-inflammation
  • Neuropathic pain
  • Post-traumatic stress disorder (PTSD)
  • Prion/Mad Cow disease
  • Rheumatoid arthritis
  • Schizophrenia
  • Stroke
  • Vomiting and nausea

Interestingly, some findings have grown out of research that was initially or primarily focused on medical marijuana use, and some research has evolved into pharmaceutical application. GW Pharmaceuticals, based in the United Kingdom, has developed Sativex, a natural cannabis extract containing equal parts CBD and THC. It has been approved in the U.K. for treatment of Multiple Sclerosis and has shown promise in the treatment of cancer pain and neuropathic pain. GW has also developed Epidiolex, a pure CBD extract which is undergoing US FDA orphan drug trials for treatment of pediatric epilepsy.

Cannabinoid research led to the UK’s approval of Sativex, a medicine for the treatment of spasticity due to Multiple Sclerosis. Click To Tweet

In addition, the study of CBD’s anti-oxidant, anti-inflammatory and neuro-protective properties are well documented. All of these properties may prove to be important in combating degenerative diseases and aging. The implications for hope in this area alone are tremendous.

There is a wealth of research available regarding the scientific studies of CBD for medicinal use. We encourage you to read further on your own for information about health conditions that may be of interest and concern to you. We anticipate exciting developments on the horizon for the application of CBD and are proud to be part of the growing hemp industry.

By |2017-07-10T15:07:37+00:00September 22nd, 2016|Hemp Facts|0 Comments

About the Author:

Leave A Comment


Your Cart